NCT05953909

A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).

Efficacy and Safety of Eribulin-Based Regimen in the Treatment of Metastatic Triple-Negative Breast Cancer and Comparison With Other Chemotherapy Regimen: A Single-Center Retrospective Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 120 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A Single-Center Retrospective Study About Efficacy and Safety of Eribulin-Based Regimen in the Treatment of Metastatic Triple-Negative Breast Cancer and Comparison With Other Chemotherapy Regimen

Detailed description

Not provided

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Eribulin-Based Regimen	Eribulin Mesylate will be administered as a 1.4 mg/m\^2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
DRUG	nab-paclitaxel based regimen	nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.
DRUG	Other Chemotherapy Regimen	TX：Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m2 D1 Q3W)+Capecitabine 850-950mg/ m\^2, BID D1-14, Q3W. GP:Gemcitabine 800-1000mg/ m\^2, D1,8 Q3W+Cisplatin 75mg/m\^2, D1-3, Q3W. AT:Epirubicin 75mg/ m 2, D1, Q3W+Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m\^2 D1 Q3W) T:Docetaxel 75mg/ m ², D1 Q3W (or paclitaxel 80mg/ m ² QW)

Timeline

• Start date: 2023-02-01
• Primary completion: 2023-08-01
• Completion: 2023-08-01
• First posted: 2023-07-20
• Last updated: 2023-07-20

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study